Aminologics Co.,Ltd.
Financials
Valuation Metrics
Aminologics Co.,Ltd.'s Market Cap is ₩896B. At end of 2025 it was ₩1067B. Ranked #1285 of 2,405 in KR market (top 53%), #702 of 1,627 on KOSDAQ (top 43%), #150 of 292 in Materials (top 51%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 89.61B KRW | KR#1,285/2,405 Sec#150/292 |
| Revenue | 26.16B KRW | KR#2,073/2,405 Sec#275/292 |
| Net Income | 3.16B KRW | KR#1,341/2,405 Sec#173/292 |
| Total Assets | 89.72B KRW | KR#1,863/2,405 Sec#255/292 |
| Net Assets | 58.43B KRW | KR#1,804/2,405 Sec#245/292 |
| Employees | 38 | KR#2,135/2,405 Sec#265/292 |
| Value | ||
| P/E | 28.37x | KR#1,312/2,405 Sec#174/292 |
| P/B | 1.53x | KR#1,834/2,405 Sec#262/292 |
| P/S | 3.43x | KR#2,052/2,405 Sec#278/292 |
| EV/EBITDA | 15.10x | KR#917/2,405 Sec#108/292 |
| Profitability | ||
| ROE | 5.41% | KR#1,052/2,405 Sec#106/292 |
| ROA | 3.52% | KR#959/2,405 Sec#103/292 |
| Op. Margin | 20.95% | KR#150/2,405 Sec#2/292 |
| Revenue Growth | 64.47% | KR#148/2,405 Sec#7/292 |
| Financial Health | ||
| Debt Ratio | 53.54% | KR#1,003/2,405 Sec#115/292 |
| Total Debt | 16.19B KRW | KR#1,458/2,405 Sec#219/292 |
| Cash | 23.08B KRW | KR#1,165/2,405 Sec#139/292 |
| Current Ratio | 2.28x | KR#758/2,405 Sec#77/292 |
| Net Debt/EBITDA | -1.26x | KR#327/2,405 Sec#37/292 |
| Performance | ||
| 1Y Return | 11.82% | KR#406/2,405 Sec#35/292 |
| 1M Return | -3.00% | KR#442/2,405 Sec#57/292 |
| From 52W High | -48.30% | KR#1,064/2,405 Sec#145/292 |
| 1Y MDD | -47.39% | KR#839/2,405 Sec#116/292 |
| Trading | ||
| Volume | 49,010 shares | KR#1,175/2,405 Sec#124/292 |
| Trading Value | 49.4M KRW | KR#1,874/2,405 Sec#212/292 |
| Foreign Own. | 2.20% | KR#1,549/2,405 Sec#183/292 |
| Per Share | ||
| EPS | 35 KRW | KR#1,517/2,405 Sec#199/292 |
| BPS | 654 KRW | KR#2,357/2,405 Sec#291/292 |
Company Info
Aminologics, established in 1997 and KOSDAQ listed in 2004, is a small and medium-sized venture enterprise. The company acquired the active pharmaceutical ingredient (API) business rights from Sam-O Pharmaceutical in 2015, supplying APIs for stroke, eye diseases, and dermatitis to domestic pharmaceutical companies. Since 2009, Aminologics has been developing various products, including D-Serine, through its amino acid derivative business. Recognized for its quality by global customers, the company is actively engaged in research and development to capture the peptide new drug market, receiving new development requests. Aminologics is headquartered in Gangnam-gu, Seoul.